The firm said it has secured US Food and Drug Administration breakthrough device designation for its test to classify infections and stratify patients by severe disease risk.
The laboratory services spinoff of Nonacus is launching sales of a next-generation sequencing-based test that could help determine which patients need cystoscopies.
The firm reported that, excluding COVID-19 testing, its molecular diagnostics business grew 15 percent and overall diagnostics business grew 11 percent.
Company officials addressed rumors that the firm may be looking to sell its IVD business, as its CEO called such reports a "distraction."
Research teams report progress in identifying the biomarkers of psychiatric disorders, and one team aims to deliver tests for use with psychiatric evaluations.
The firm reported its immunodiagnostics revenues rose on strong sales in Europe and North America while molecular instrument sales normalized from previous highs.
The firm is expanding its lab capabilities and leveraging its test development reputation to form partnerships early in the drug development process.
The firm reported its diagnostics revenues were down about 9 percent, while its life sciences revenues dipped 2 percent.
The firm is using infrared spectroscopy to fill a testing need it discovered while developing a newer type of anticoagulant drug that has overtaken warfarin recently in popularity.
The UK-based firm plans to finish development in the coming year of multiplex lateral flow assays for detection of multiple diseases or management of single diseases.